Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
2.2600
+0.1900 (9.18%)
NASDAQ · Last Trade: Apr 20th, 4:58 AM EDT
Detailed Quote
Previous Close | 2.070 |
---|---|
Open | 1.930 |
Bid | 2.180 |
Ask | 2.250 |
Day's Range | 1.900 - 2.490 |
52 Week Range | 1.720 - 20.28 |
Volume | 1,321,908 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 397,300 |
Chart
About Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
Redhill Biopharma is a biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and other serious conditions. The company specializes in creating novel formulations and repurposing existing drugs to improve treatment outcomes for patients. Redhill is dedicated to addressing unmet medical needs through its robust pipeline of products, which includes both clinical-stage candidates and marketed drugs. By leveraging advanced scientific research and a strategic approach to drug development, Redhill aims to improve the lives of patients suffering from complex health issues. Read More
News & Press Releases
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · April 17, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · April 16, 2025
Via Benzinga · April 16, 2025

Via Benzinga · February 13, 2025

One of today's biggest market movers in the biotech space is RedHill Biuopharma, with RDHL stock up more than 75% on big news.
Via InvestorPlace · August 1, 2024

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance
Via News Direct · February 5, 2025

Via Benzinga · January 21, 2025

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit
Via News Direct · December 9, 2024

RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment
Via News Direct · October 15, 2024

Via Benzinga · October 3, 2024

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
Via News Direct · August 23, 2024

RedHill Biopharma released study results showing opaganib's potential in treating Type 2 diabetes and obesity. The drug's ability to target sphingolipid metabolism could help prevent weight gain and improve glucose tolerance.
Via Benzinga · August 19, 2024

Via Benzinga · August 1, 2024

Via Benzinga · June 18, 2024

Via Benzinga · February 1, 2024

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also rose, gaining, 0.19% to 4,877.88.
Via Benzinga · January 25, 2024

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via Benzinga · January 25, 2024

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28.
Via Benzinga · January 25, 2024

Via Benzinga · January 25, 2024

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.33% to 37,932.33 while the NASDAQ rose 0.37% to 15,538.69. The S&P 500 also rose, gaining, 0.40% to 4,887.88.
Via Benzinga · January 25, 2024

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
Via Benzinga · January 24, 2024

Via Benzinga · January 24, 2024

Redhill Biopharma Ltd. shares are trading higher Wednesday after the company was granted a patent for a method for eradicating helicobacter pylori infections in patients regardless of body mass index.
Via Benzinga · January 24, 2024